CIPLA LTD vs NATCO PHARMA LTD.

A side-by-side comparison of CIPLA LTD (CIPLA) and NATCO PHARMA LTD. (NATCOPHARM) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, NATCO PHARMA LTD. leads CIPLA vs NATCOPHARM on 9 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

Valuation

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

29.54
P/E ratio
11.93
3.42
P/B ratio
1.81
0.90%
Dividend yield
0.52%
₹48.02
EPS
₹79.20

Profitability

How efficiently each company turns capital and sales into profit. Higher is better.

11.60%
Return on equity
16.90%
15.00%
Return on capital
17.00%
21.00%
EBITDA margin
35.00%
13.71%
Net margin
34.77%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

7.37%
Revenue CAGR (3Y)
14.64%
10.88%
Profit CAGR (3Y)
25.64%

Size & financial health

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹1.15L Cr
Market cap
₹16,932 Cr
₹28,163 Cr
Revenue
₹4,078 Cr
₹3,862 Cr
Net profit
₹1,418 Cr
0.02
Debt / equity
0.08
CIPLA LTD
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 25.7%"]
  • ["The company has delivered a poor sales growth of 8.01% over past five years.", "Promoter holding has decreased over last 3 years: -4.34%"]
NATCO PHARMA LTD.
  • + ["Company is almost debt free.", "Company has delivered good profit growth of 27.7% CAGR over last 5 years"]
  • ["Tax rate seems low"]
CIPLA LTD full analysis NATCO PHARMA LTD. full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.